RMBB Health

RMBB is a clinical-stage biotechnology company focused on the discovery and development of transformative medicines for metabolic diseases, including obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). Founded by Dr. Rui-Ping Xiao, a renowned expert in cardiovascular and metabolic research, the company utilizes a deep understanding of G-protein coupled receptor (GPCR) signaling to design multi-targeting agonists. Its lead candidate, RMBB-001, is a tri-agonist targeting GLP-1, GIP, and glucagon receptors, currently in clinical development for weight management. RMBB's pipeline also includes next-generation oral small molecules and long-acting peptides aimed at improving patient outcomes in the rapidly evolving metabolic health landscape. The company is backed by leading venture capital firms and maintains a strong focus on scientific innovation in the metabolic space.